Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review

Journal of the American College of Cardiology

Volumn 75, Issue 4, 2020, Pages 435-447

  Zelniker, Thomas A ^a   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cardiorenal interaction; diabetes; heart failure; renal function; sodium glucose cotransporter 2 inhibitor

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; ANTIDIABETIC AGENT;

ALL CAUSE MORTALITY; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; CARDIOVASCULAR DISEASE; COMPLICATION; DISEASE EXACERBATION; GLUCOSE BLOOD LEVEL; HEART; KIDNEY; PHARMACOLOGY; RISK;

ATHEROSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEART; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; RISK; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85078024987     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.11.036     Document Type: Review

References (59)

1. Petersen, C., Analyse des phloridzins. Annalen der Pharmacie, 15, 1835, 178.
2. von Mering, J., Über künstlichen diabetes. Centralblatt fur die medizinische Wissenschaft, 22, 1886, 531.
3. Wang, Y., Lou, Y., Wang, J., et al. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Eur J Med Chem 180 (2019), 398–416.
4. Zelniker, T.A., Wiviott, S.D., Raz, I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
5. Perkovic, V., Jardine, M.J., Neal, B., et al., for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (2019), 2295–2306.
6. Zelniker, T.A., Braunwald, E., Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75 (2020), 422–435.
7. Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
8. Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
9. Wiviott, S.D., Raz, I., Bonaca, M.P., et al., for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
10. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al., for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (2019), 1995–2008.
11. Fitchett, D., Inzucchi, S.E., Cannon, C.P., et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139 (2019), 1384–1395.
12. Fitchett, D., Zinman, B., Wanner, C., et al., for the EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
13. Fitchett, D.H., Inzucchi, S.E., Sambevski, S., et al. Empagliflozin reduces mortality and hospitalization for heart failure in patients with or without a history of myocardial infarction or stroke at baseline (abstr). J Am Coll Cardiol 71 (2018), 364–367.
14. Verma, S., Mazer, C.D., Bhatt, D.L., et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. Diabetes Care 42 (2019), e42–e44.
15. Savarese, G., Sattar, N., Januzzi, J., et al. Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality. Circulation 139 (2019), 1458–1460.
16. Furtado, R.H.M., Bonaca, M.P., Raz, I., et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 Trial. Circulation 139 (2019), 2516–2527.
17. Thygesen, K., Alpert, J.S., Jaffe, A.S., et al., for the Joint European Society of Cardiology /American College of Cardiology /American Heart Association/World Heart Federation Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 72 (2018), 2231–2264.
18. Figtree, G.A., Radholm, K., Barrett, T.D., et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes. Circulation 139 (2019), 2591–2593.
19. Kato, E.T., Silverman, M.G., Mosenzon, O., et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139 (2019), 2528–2536.
20. Verma, S., Mazer, C.D., Yan, A.T., et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation 140 (2019), 1693–1702.
21. Januzzi, J.L. Jr., Butler, J., Jarolim, P., et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70 (2017), 704–712.
22. Nassif, M.E., Windsor, S.L., Tang, F., et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140 (2019), 1463–1476.
23. McMurray, J.J.V., DeMets, D.L., Inzucchi, S.E., et al., for the DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 21 (2019), 665–675.
24. McMurray, J.J.V., DeMets, D.L., Inzucchi, S.E., et al., for the DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 21 (2019), 1402–1411.
25. Wanner, C., Heerspink, H.J.L., Zinman, B., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol 29 (2018), 2755–2769.
26. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
27. Perkovic, V., de Zeeuw, D., Mahaffey, K.W., et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
28. Mosenzon, O., Wiviott, S.D., Cahn, A., et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7 (2019), 606–617.
29. Neuen, B.L., Young, T., Heerspink, H.J.L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (2019), 845–854.
30. Butler, J., Zannad, F., Fitchett, D., et al. Empagliflozin improves kidney outcomes in patients with or without heart failure. Circ Heart Fail, 12, 2019, e005875.
31. Neuen, B.L., Ohkuma, T., Neal, B., et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 138 (2018), 1537–1550.
32. Wanner, C., Lachin, J.M., Inzucchi, S.E., et al., EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
33. Lega, I.C., Bronskill, S.E., Campitelli, M.A., et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infections: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21 (2019), 2394–2404.
34. U.S. Food and Drug Administration. FDA Warns About Rare Occurrences of a Serious Infection of the Genital Area With SGLT2 Inhibitors for Diabetes. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm, August 29, 2018. (Accessed 12 November 2019)
35. Bersoff-Matcha, S.J., Chamberlain, C., Cao, C., Kortepeter, C., Chong, W.H., Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 170 (2019), 764–769.
36. Meyer, E.J., Gabb, G., Jesudason, D., SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care 41 (2018), e47–e49.
37. Matthews, D.R., Li, Q., Perkovic, V., et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. Diabetologia 62 (2019), 926–938.
38. Katsiki, N., Dimitriadis, G., Hahalis, G., et al. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism 96 (2019), 92–100.
39. Fralick, M., Kim, S.C., Schneeweiss, S., Kim, D., Redelmeier, D.A., Patorno, E., Fracture risk after initiation of use of canagliflozin: a cohort study. Ann Intern Med, 171, 2019, 80.
40. Henry, R.R., Thakkar, P., Tong, C., Polidori, D., Alba, M., Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38 (2015), 2258–2265.
41. Dandona, P., Mathieu, C., Phillip, M., et al., for the DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5 (2017), 864–876.
42. Mathieu, C., Dandona, P., Gillard, P., et al., for the DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 41 (2018), 1938–1946.
43. Rosenstock, J., Marquard, J., Laffel, L.M., et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41 (2018), 2560–2569.
44. Garg, S.K., Henry, R.R., Banks, P., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377 (2017), 2337–2348.
45. McCrimmon, R.J., Henry, R.R., SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 61 (2018), 2126–2133.
46. Yamada, T., Shojima, N., Noma, H., Yamauchi, T., Kadowaki, T., Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 20 (2018), 1755–1761.
47. Dandona, P., Mathieu, C., Phillip, M., et al., for the DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 41 (2018), 2552–2559.
48. Danne, T., Pettus, J., Giaccari, A., et al. Sotagliflozin added to optimized insulin therapy leads to lower rates of clinically relevant hypoglycemic events at any HbA1c at 52 weeks in adults with type 1 diabetes. Diabetes Technol Ther 21 (2019), 471–477.
49. Das, S.R., Everett, B.M., Birtcher, K.K., et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 72 (2018), 3200–3223.
50. Davies, M.J., D'Alessio, D.A., Fradkin, J., et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (2018), 2669–2701.
51. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care 42 Suppl 1 (2019), S90–S102.
52. Arnett, D.K., Blumenthal, R.S., Albert, M.A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 74 (2019), 1376–1414.
53. Deerochanawong, C., Chan, S.P., Matawaran, B.J., et al. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations. Diabetes Obes Metab 21 (2019), 2354–2367.
54. Cosentino, F., Grant, P.J., Aboyans, V., et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 40 (2019), 3215–3217.
55. Berg, D.D., Wiviott, S.D., Scirica, B.M., et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation 140 (2019), 1569–1577.
56. Ito, H., Shinozaki, M., Nishio, S., Abe, M., SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opin Pharmacother 17 (2016), 2073–2084.
57. Dominguez Rieg, J.A., Rieg, T., What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition. Diabetes Obes Metab 21 Suppl 2 (2019), 43–52.
58. Cannon, C.P., McGuire, D.K., Pratley, R., et al., for the VERTIS-CV Investigators. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 206 (2018), 11–23.
59. Valensi, P., Picard, S., Pathak, A., Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?. Diabetes Metab 45 (2019), 501–504.